These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 3724805)

  • 21. [Methods of correcting hyperphosphatemia in chronic renal failure and in dialysis (review)].
    Novikov AI
    Ter Arkh; 1997; 69(12):63-7. PubMed ID: 9503540
    [No Abstract]   [Full Text] [Related]  

  • 22. Calcium carbonate in hyperphosphatemia.
    Mayo M; Middleton RK
    DICP; 1991 Sep; 25(9):945-7. PubMed ID: 1949973
    [No Abstract]   [Full Text] [Related]  

  • 23. Does concomitant administration of sevelamer and calcium carbonate modify the control of phosphatemia?
    Ouellet G; Cardinal H; Mailhot M; Ste-Marie LG; Roy L
    Ther Apher Dial; 2010 Apr; 14(2):172-7. PubMed ID: 20438539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Control of hyperphosphatemia among patients with ESRD.
    Coladonato JA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Calcium carbonate: a suitable alternative to aluminum hydroxide as phosphate binder.
    Malberti F; Surian M; Colussi G; Poggio F; Minoia C; Salvadeo A
    Kidney Int Suppl; 1988 Mar; 24():S184-5. PubMed ID: 3163047
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of histamine H2-receptor antagonists on the phosphorus-binding ability of phosphate binders in hemodialysis patients].
    Takahashi N; Yuasa S; Hitomi H; Hashimoto M; Kiyomoto H; Uchida K; Shoji T; Hirohata M; Matsuo H
    Nihon Jinzo Gakkai Shi; 1996 Dec; 38(12):610-7. PubMed ID: 9014481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
    Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
    J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Phosphate binder up to date].
    Shigematsu T; Sakaguchi T; Orita H
    Clin Calcium; 2007 May; 17(5):772-8. PubMed ID: 17471009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Calcium carbonate as a phosphate binder in dialysis patients: evaluation of an enteric-coated preparation and effect of additional aluminium hydroxide on hyperaluminaemia.
    Ittel TH; Schäfer C; Schmitt H; Gladziwa U; Sieberth HG
    Klin Wochenschr; 1991 Jan; 69(2):59-67. PubMed ID: 2027271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hyperphosphatemia: its consequences and treatment in patients with chronic renal disease.
    Delmez JA; Slatopolsky E
    Am J Kidney Dis; 1992 Apr; 19(4):303-17. PubMed ID: 1562018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure.
    Andreoli SP; Dunson JW; Bergstein JM
    Am J Kidney Dis; 1987 Mar; 9(3):206-10. PubMed ID: 3826069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
    Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskühler A
    Nephron Clin Pract; 2006; 102(2):c61-71. PubMed ID: 16224198
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A comparison of phosphorus-chelating effect of calcium carbonate versus calcium acetate before dialysis].
    Borrego J; Pérez del Barrio P; Serrano P; García Cortés MJ; Sánchez Perales MC; Borrego FJ; Liébana A; Gil Cunquero JM; Pérez Bañasco V
    Nefrologia; 2000; 20(4):348-54. PubMed ID: 11039260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of calcium carbonate to treat the hyperphosphataemia of chronic renal failure.
    Williams B; Vennegoor M; O'Nunan T; Walls J
    Nephrol Dial Transplant; 1989; 4(8):725-9. PubMed ID: 2510082
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Calcium carbonate. A better phosphate binder than aluminum hydroxide.
    Lerner A; Kramer M; Goldstein S; Caruana R; Epstein S; Raja R
    ASAIO Trans; 1986; 32(1):315-8. PubMed ID: 3535845
    [No Abstract]   [Full Text] [Related]  

  • 36. Calcium carbonate as a phosphate binder in hemodialysis patients.
    Taber TE; Hegemen TF; York S
    ASAIO Trans; 1986; 32(1):127-9. PubMed ID: 3778697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism.
    Slatopolsky E; Weerts C; Norwood K; Giles K; Fryer P; Finch J; Windus D; Delmez J
    Kidney Int; 1989 Nov; 36(5):897-903. PubMed ID: 2615197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis.
    Okada K; Takahashi S; Nagura Y; Hatano M
    Nihon Jinzo Gakkai Shi; 1989 Oct; 31(10):1085-9. PubMed ID: 2615019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term suppression of hyperparathyroidism by phosphate binders in uremic children.
    Tamanaha K; Mak RH; Rigden SP; Turner C; Start KM; Haycock GB; Chantler C
    Pediatr Nephrol; 1987 Apr; 1(2):145-9. PubMed ID: 3153271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The clinical management of hyperphosphatemia.
    Ritz E
    J Nephrol; 2005; 18(3):221-8. PubMed ID: 16013007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.